Amandine Crombé1,2, Cynthia Périer2, Michèle Kind1, Baudouin Denis De Senneville2, François Le Loarer3, Antoine Italiano4, Xavier Buy1, Olivier Saut2. 1. Department of Radiology, Institut Bergonie, Regional Comprehensive Cancer Center, Bordeaux, France. 2. University of Bordeaux, IMB, UMR CNRS 5251, INRIA Project team Monc, Talence, France. 3. Department of Pathology, Institut Bergonie, Regional Comprehensive Cancer Center, Bordeaux, France. 4. Department of Medical Oncology, Institut Bergonie, Regional Comprehensive Cancer Center, Bordeaux, France.
Abstract
BACKGROUND: Standard of care for patients with high-grade soft-tissue sarcoma (STS) are being redefined since neoadjuvant chemotherapy (NAC) has demonstrated a positive effect on patients' outcome. Yet response evaluation in clinical trials still relies on RECIST criteria. PURPOSE: To investigate the added value of a Delta-radiomics approach for early response prediction in patients with STS undergoing NAC. STUDY TYPE: Retrospective. POPULATION: Sixty-five adult patients with newly-diagnosed, locally-advanced, histologically proven high-grade STS of trunk and extremities. All were treated by anthracycline-based NAC followed by surgery and had available MRI at baseline and after two chemotherapy cycles. FIELD STRENGTH/SEQUENCE: Pre- and postcontrast enhanced T1 -weighted imaging (T1 -WI), turbo spin echo T2 -WI at 1.5 T. ASSESSMENT: A threshold of <10% viable cells on surgical specimens defined good response (Good-HR). Two senior radiologists performed a semantic analysis of the MRI. After 3D manual segmentation of tumors at baseline and early evaluation, and standardization of voxel-sizes and intensities, absolute changes in 33 texture and shape features were calculated. STATISTICAL TESTS: Classification models based on logistic regression, support vector machine, k-nearest neighbors, and random forests were elaborated using crossvalidation (training and validation) on 50 patients ("training cohort") and was validated on 15 other patients ("test cohort"). RESULTS: Sixteen patients were good-HR. Neither RECIST status (P = 0.112) nor semantic radiological variables were associated with response (range of P-values: 0.134-0.490) except an edema decrease (P = 0.003), although 14 shape and texture features were (range of P-values: 0.002-0.037). On the training cohort, the highest diagnostic performances were obtained with random forests built on three features: Δ_Histogram_Entropy, Δ_Elongation, Δ_Surrounding_Edema, which provided: area under the curve the receiver operating characteristic = 0.86, accuracy = 88.1%, sensitivity = 94.1%, and specificity = 66.3%. On the test cohort, this model provided an accuracy of 74.6% but 3/5 good-HR were systematically ill-classified. DATA CONCLUSION: A T2 -based Delta-radiomics approach might improve early response assessment in STS patients with a limited number of features. LEVEL OF EVIDENCE: 3 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2019;50:497-510.
BACKGROUND: Standard of care for patients with high-grade soft-tissue sarcoma (STS) are being redefined since neoadjuvant chemotherapy (NAC) has demonstrated a positive effect on patients' outcome. Yet response evaluation in clinical trials still relies on RECIST criteria. PURPOSE: To investigate the added value of a Delta-radiomics approach for early response prediction in patients with STS undergoing NAC. STUDY TYPE: Retrospective. POPULATION: Sixty-five adult patients with newly-diagnosed, locally-advanced, histologically proven high-grade STS of trunk and extremities. All were treated by anthracycline-based NAC followed by surgery and had available MRI at baseline and after two chemotherapy cycles. FIELD STRENGTH/SEQUENCE: Pre- and postcontrast enhanced T1 -weighted imaging (T1 -WI), turbo spin echo T2 -WI at 1.5 T. ASSESSMENT: A threshold of <10% viable cells on surgical specimens defined good response (Good-HR). Two senior radiologists performed a semantic analysis of the MRI. After 3D manual segmentation of tumors at baseline and early evaluation, and standardization of voxel-sizes and intensities, absolute changes in 33 texture and shape features were calculated. STATISTICAL TESTS: Classification models based on logistic regression, support vector machine, k-nearest neighbors, and random forests were elaborated using crossvalidation (training and validation) on 50 patients ("training cohort") and was validated on 15 other patients ("test cohort"). RESULTS: Sixteen patients were good-HR. Neither RECIST status (P = 0.112) nor semantic radiological variables were associated with response (range of P-values: 0.134-0.490) except an edema decrease (P = 0.003), although 14 shape and texture features were (range of P-values: 0.002-0.037). On the training cohort, the highest diagnostic performances were obtained with random forests built on three features: Δ_Histogram_Entropy, Δ_Elongation, Δ_Surrounding_Edema, which provided: area under the curve the receiver operating characteristic = 0.86, accuracy = 88.1%, sensitivity = 94.1%, and specificity = 66.3%. On the test cohort, this model provided an accuracy of 74.6% but 3/5 good-HR were systematically ill-classified. DATA CONCLUSION: A T2 -based Delta-radiomics approach might improve early response assessment in STS patients with a limited number of features. LEVEL OF EVIDENCE: 3 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2019;50:497-510.
Authors: Brandon K K Fields; Natalie L Demirjian; Darryl H Hwang; Bino A Varghese; Steven Y Cen; Xiaomeng Lei; Bhushan Desai; Vinay Duddalwar; George R Matcuk Journal: Eur Radiol Date: 2021-04-23 Impact factor: 5.315
Authors: Daniel T Huff; Peter Ferjancic; Mauro Namías; Hamid Emamekhoo; Scott B Perlman; Robert Jeraj Journal: Biomed Phys Eng Express Date: 2021-09-30
Authors: Amani Arthur; Edward W Johnston; Jessica M Winfield; Matthew D Blackledge; Robin L Jones; Paul H Huang; Christina Messiou Journal: Front Oncol Date: 2022-07-01 Impact factor: 5.738
Authors: Ty K Subhawong; Katharina Feister; Kevin Sweet; Noam Alperin; Deukwoo Kwon; Andrew Rosenberg; Jonathan Trent; Breelyn A Wilky Journal: Radiol Imaging Cancer Date: 2021-07